Letter to the editor concerning "Single-institution experience of performing bloodless transplant in Jehovah's Witness patients" by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol oncol stem cell ther 2019;12(1):44-9.)
- PMID: 31628925
- DOI: 10.1016/j.hemonc.2019.08.007
Letter to the editor concerning "Single-institution experience of performing bloodless transplant in Jehovah's Witness patients" by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol oncol stem cell ther 2019;12(1):44-9.)
Conflict of interest statement
Declaration of Competing Interest S.U. receives research funding from Amgen, Array Biopharma, BMS, Celgene, Janssen, Merck, Pharmacyclics, Sanofi, and Takeda. S.U. is a Consultant for Amgen, BMS, Celgene, Janssen, Merck, SkylineDx, and Takeda, and is a Speaker for Amgen, Celgene, Janssen, Sanofi, and Takeda. S.A. receives consulting honorarium from Takeda, Amgen, and Celgene. J.C.Z., J.R.A., and A.L.M. have nothing to disclose.
Comment on
-
A single-institution experience of performing bloodless transplant in Jehovah's Witness patients.Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):44-49. doi: 10.1016/j.hemonc.2018.11.003. Epub 2018 Dec 27. Hematol Oncol Stem Cell Ther. 2019. PMID: 30605629 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
